[144] PULSE BIOSCIENCES, INC. SEC Filing

Rhea-AI Filing Summary

Form 144 filed for Pulse Biosciences, Inc. (PLSE) reports a proposed sale of 25,000 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $406,750.00. The filing states the shares were acquired and paid for on 09/18/2025 by exercise of stock options from the issuer, and the approximate date of sale is also listed as 09/18/2025.

The filing lists 67,278,347 shares outstanding, and no other sales by the reporting person in the past three months were reported. The filer represents there is no undisclosed material adverse information and includes the standard signed certification language on trading plans and criminal penalties for false statements.

Insights

Securities Analyst

TL;DR: Insider plans to sell exercised option shares equal to $406,750; size versus outstanding shares is small.

The notice documents a proposed sale of 25,000 common shares acquired by option exercise on 09/18/2025 and routed through Morgan Stanley Smith Barney LLC. The aggregate value is $406,750 relative to 67,278,347 shares outstanding. This submission is a routine Rule 144 notice reflecting a planned disposition rather than an extraordinary corporate event. The filing contains no earnings, financing, or governance changes and discloses no prior sales in the last three months.

Corporate Governance Expert

TL;DR: Form 144 shows a compliant, signed insider sale notice tied to option exercise; disclosure is standard.

The document states the securities were acquired via exercise of stock options from the issuer and that payment was made in cash on 09/18/2025. The filer affirms no undisclosed material adverse information and references Rule 10b5-1 trading plan language. There are no indications of extraordinary governance actions or material company developments in this filing.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	25000	406750.00	67278347	09/18/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/18/2025	Exercise of Stock Options	Issuer			25000	09/18/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did the Form 144 for Pulse Biosciences (PLSE) disclose?

The filing discloses a proposed sale of 25,000 common shares with an aggregate market value of $406,750.00, through Morgan Stanley Smith Barney LLC, with an approximate sale date of 09/18/2025.

How were the 25,000 shares acquired according to the filing?

The shares were acquired on 09/18/2025 by exercise of stock options from the issuer, with payment made in cash on the same date.

Does the filing report other recent sales by the same person?

No. The section for securities sold during the past three months states "Nothing to Report".

Which broker is handling the proposed sale listed on the Form 144?

The broker named is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.

How many shares outstanding does the filing list for Pulse Biosciences?

The filing lists 67,278,347 shares outstanding.